Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC

Background Anti-programmed cell death 1 (PD-1) antibody combined with chemotherapy simultaneously is regarded as the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) by current clinical guidelines. Different immune statuses induced by chemotherapy considerably affect...

Full description

Saved in:
Bibliographic Details
Main Authors: Hong Liu, Li Liu, Na Han, Dan Wang, Ting Sun, Zhixin Zhang, Yi Zhang, Liping Wang, Wei Lv, Hongmin Wang, Lihua Liu, Shundong Cang, Yujie Xu, Guohui Qin, Yachang Huo, Shuangning Yang, Chenhui Zhao, Qingyang Lei, Qitai Zhao, Yaqing Liu, Kaiyuan Guo, Songyun Ouyang, Feifei Fan, Hongjie Chen, Lijun Miao, Yuqing Duan
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/12/e009627.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/12/e009627.full

Similar Items